Literature DB >> 12947370

Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft.

Laurent Leborgne1, Edouard Cheneau, Augusto Pichard, Andrew Ajani, Rajbabu Pakala, Hamid Yazdi, Lowell Satler, Kenneth Kent, William O Suddath, Ellen Pinnow, Daniel Canos, Ron Waksman.   

Abstract

BACKGROUND: Percutaneous coronary intervention (PCI) of saphenous vein graft (SVG) is associated with frequent postprocedural enzyme elevation and late cardiac events. New strategies are proposed to minimize distal embolization and to improve the outcome of patients treated with stenting for SVG lesions. The objectives of the current study were to examine direct stenting (DS) strategy of PCI in SVG lesions and its effects on creatine-kinase (CK) release, major adverse cardiac events (MACE), and late outcome when compared to conventional stenting (CS).
METHODS: A consecutive series of 527 patients treated with stent implantation for SVG stenosis was analyzed. In this cohort, 170 patients with 229 lesions were treated with DS and 357 patients with 443 lesions were treated with CS. The inhospital and 12-month follow-up events were recorded and reported.
RESULTS: Baseline clinical and postprocedural angiographic characteristics were similar between the 2 groups except for higher preprocedural prevalence of thrombus-containing lesions in the DS group. Patients in the DS group had less CK-MB release (P <.001), and less non-Q-wave myocardial infarction (P =.024). Multivariate analysis detected unstable angina (odds ratio [OR] = 1.8, P =.03) as a correlate for non-Q-wave MI; DS was inversely associated with non-Q-wave myocardial infarction (OR = 0.65, P =.04). At 1 year, the target lesion revascularization-MACE was significantly lower in the DS group (P =.021). Multivariate analysis showed that DS (OR = 0.47, P =.007) was associated with reduction of the target lesion revascularization-MACE.
CONCLUSIONS: When feasible, DS may be the best approach for treating SVG stenosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947370     DOI: 10.1016/S0002-8703(03)00309-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

Review 1.  An update on coronary bypass graft intervention.

Authors:  Debabrata Dash
Journal:  Heart Asia       Date:  2014-03-06

2.  Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial.

Authors:  Faisal Latif; Lauren Uyeda; Robert Edson; Deepak L Bhatt; Steven Goldman; David R Holmes; Sunil V Rao; Kendrick Shunk; Kul Aggarwal; Barry Uretsky; Islam Bolad; Khaled Ziada; Edward McFalls; Anand Irimpen; Huu Tam Truong; Scott Kinlay; Vasilios Papademetriou; Raghava S Velagaleti; Bavana V Rangan; Kreton Mavromatis; Mei-Chiung Shih; Subhash Banerjee; Emmanouil S Brilakis
Journal:  Circ Cardiovasc Interv       Date:  2020-02-05       Impact factor: 6.546

3.  Current State of the Art in Approaches to Saphenous Vein Graft Interventions.

Authors:  Michael Lee; Jeremy Kong
Journal:  Interv Cardiol       Date:  2017-09

4.  Procedural Results and Immediate Outcomes following De Novo Saphenous Venous Graft Interventions.

Authors:  Lalita Nemani; Maddury Jyotsna; Malleswara Rao D
Journal:  Int J Angiol       Date:  2018-03-26

5.  Long-term outcomes of percutaneous coronary interventions within coronary artery bypass grafts.

Authors:  Rafał Januszek; Zbigniew Siudak; Artur Dziewierz; Tomasz Rakowski; Dariusz Dudek; Stanisław Bartuś
Journal:  Arch Med Sci       Date:  2019-01-30       Impact factor: 3.318

6.  Endovascular stenting of an extracranial-intracranial saphenous vein high-flow bypass graft: Technical case report.

Authors:  Giuliano Maselli; Claudio De Tommasi; Alessandro Ricci; Massimo Gallucci; Renato J Galzio
Journal:  Surg Neurol Int       Date:  2011-04-19

7.  Treatment of saphenous vein graft disease: "never ending story" of the "eternal return".

Authors:  Luca Testa; Francesco Bedogni
Journal:  Res Cardiovasc Med       Date:  2014-07-28

8.  Aspirate from human stented saphenous vein grafts induces epicardial coronary vasoconstriction and impairs perfusion and left ventricular function in rat bioassay hearts with pharmacologically induced endothelial dysfunction.

Authors:  Helmut R Lieder; Theodor Baars; Philipp Kahlert; Petra Kleinbongard
Journal:  Physiol Rep       Date:  2016-08

9.  Coronary aspirate TNFα reflects saphenous vein bypass graft restenosis risk in diabetic patients.

Authors:  Theodor Baars; Thomas Konorza; Philipp Kahlert; Stefan Möhlenkamp; Raimund Erbel; Gerd Heusch; Petra Kleinbongard
Journal:  Cardiovasc Diabetol       Date:  2013-01-10       Impact factor: 9.951

10.  Release of Intracoronary Microparticles during Stent Implantation into Stable Atherosclerotic Lesions under Protection with an Aspiration Device.

Authors:  Patrick Horn; Theodor Baars; Philipp Kahlert; Christian Heiss; Ralf Westenfeld; Malte Kelm; Raimund Erbel; Gerd Heusch; Petra Kleinbongard
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.